394 related articles for article (PubMed ID: 16517276)
1. Testicular germ-cell cancer.
Horwich A; Shipley J; Huddart R
Lancet; 2006 Mar; 367(9512):754-65. PubMed ID: 16517276
[TBL] [Abstract][Full Text] [Related]
2. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cell biology of testicular germ cell tumors.
Chieffi P; Franco R; Portella G
Int Rev Cell Mol Biol; 2009; 278():277-308. PubMed ID: 19815181
[TBL] [Abstract][Full Text] [Related]
4. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.
Wheater MJ; Manners J; Nolan L; Simmonds PD; Hayes MC; Mead GM
BJU Int; 2011 Dec; 108(11):1794-9. PubMed ID: 21627751
[TBL] [Abstract][Full Text] [Related]
5. Metachronous bilateral testicular germ cell tumors: report of two cases.
James FV; Kumar A; Jayaprakash PG; Mathews A
J Cancer Res Ther; 2009; 5(3):206-7. PubMed ID: 19841564
[TBL] [Abstract][Full Text] [Related]
6. Surveillance or adjuvant treatments in stage 1 testis germ-cell tumours.
Cullen M
Ann Oncol; 2012 Sep; 23 Suppl 10():x342-8. PubMed ID: 22987989
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive factors in testicular cancer.
Facchini G; Rossetti S; Berretta M; Cavaliere C; D'Aniello C; Iovane G; Mollo G; Capasso M; Della Pepa C; Pesce L; Facchini S; Imbimbo C; Pisconti S
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3885-3891. PubMed ID: 31115016
[TBL] [Abstract][Full Text] [Related]
8. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma.
Biermann K; Göke F; Nettersheim D; Eckert D; Zhou H; Kahl P; Gashaw I; Schorle H; Büttner R
J Pathol; 2007 Nov; 213(3):311-8. PubMed ID: 17768701
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study.
Aparicio J; Maroto P; del Muro XG; Gumà J; Sánchez-Muñoz A; Margelí M; Doménech M; Bastús R; Fernández A; López-Brea M; Terrassa J; Meana A; del Prado PM; Sastre J; Satrústegui JJ; Gironés R; Robert L; Germà JR
J Clin Oncol; 2011 Dec; 29(35):4677-81. PubMed ID: 22042940
[TBL] [Abstract][Full Text] [Related]
10. Stage II seminomas and nonseminomas.
Chung PW; Bedard P
Hematol Oncol Clin North Am; 2011 Jun; 25(3):529-41,viii. PubMed ID: 21570607
[TBL] [Abstract][Full Text] [Related]
11. Tumors of the Testis: Morphologic Features and Molecular Alterations.
Howitt BE; Berney DM
Surg Pathol Clin; 2015 Dec; 8(4):687-716. PubMed ID: 26612222
[TBL] [Abstract][Full Text] [Related]
12. [Embryonal germ cells and germ cell tumors].
Biermann K; Heukamp LC; Nettersheim D; Steger K; Zhou H; Franke FE; Guetgemann I; Sonnack V; Brehm R; Berg J; Bastian PJ; Müller SC; Wang-Eckert L; Schorle H; Büttner R
Verh Dtsch Ges Pathol; 2007; 91():39-48. PubMed ID: 18314594
[TBL] [Abstract][Full Text] [Related]
13. Testicular germ cell tumors: biology and clinical update.
Mannuel HD; Mitikiri N; Khan M; Hussain A
Curr Opin Oncol; 2012 May; 24(3):266-71. PubMed ID: 22343384
[TBL] [Abstract][Full Text] [Related]
14. [Clinical presentation of testicular germinal cancer].
Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
[TBL] [Abstract][Full Text] [Related]
15. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
16. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.
Jostes S; Nettersheim D; Fellermeyer M; Schneider S; Hafezi F; Honecker F; Schumacher V; Geyer M; Kristiansen G; Schorle H
J Cell Mol Med; 2017 Jul; 21(7):1300-1314. PubMed ID: 28026145
[TBL] [Abstract][Full Text] [Related]
17. [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours].
Kempkensteffen C; Hinz S; Jäger T; Weikert S; Krause H; Schostak M; Christoph F; Strenziok R; Miller K; Schrader M
Aktuelle Urol; 2008 Nov; 39(6):436-41. PubMed ID: 18979398
[TBL] [Abstract][Full Text] [Related]
18. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of "late" in the management of late relapse after treatment for a germ cell tumor.
Toner GC
J Clin Oncol; 2008 Dec; 26(34):5502-3. PubMed ID: 18936469
[No Abstract] [Full Text] [Related]
20. The chemosensitivity of testicular germ cell tumors.
Voutsadakis IA
Cell Oncol (Dordr); 2014 Apr; 37(2):79-94. PubMed ID: 24692098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
